logo-loader
AIM:VRP

Verona Pharma

Receive alerts
Market:
AIM
Market Cap:
£52.71 m
Price
49.50 GBX
Change
0.00%
52 weeks high
102.00
52 weeks low
28.60

In brief

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Deep dive We explore the investor case for growth companies

Snapshot

  • AIM-listed biotech developing respiratory disease treatments
  • Nebulizer version of COPD drug expected to enter phase III trial later this year
  • COPD a major cause of death globally